In lung cancer model, its activation is sufficient to cause resistance to EGFR-TKI, while its chemical inhibition reduces cell proliferation under EGFR-TKI and increases apoptosis in vitro and in a PDX model [124]. This evidence concerns the gene EGFR and lung carcinoma.